The Experts below are selected from a list of 10152 Experts worldwide ranked by ideXlab platform

Christopher Kalberg - One of the best experts on this subject based on the ideXlab platform.

  • effect of Fluticasone Propionate salmeterol 250 50 μg or salmeterol 50 μg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    Summary Objectives COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50μg twice daily on moderate to severe exacerbations. Methods Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. Results In 782 patients with COPD (mean FEV 1 =0.94±0.36L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p p =0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% ( p Conclusions We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • effect of Fluticasone Propionate salmeterol 250 50 microg or salmeterol 50 microg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). Clinical improvements observed during run-in treatment with Fluticasone Propionate/salmeterol 250/50 were better maintained over 12 months with Fluticasone Propionate/salmeterol 250/50 than salmeterol. Adverse events were reported for a similar percentage of subjects across groups. A higher reporting of pneumonia was observed with Fluticasone Propionate/salmeterol 250/50 than salmeterol (7% vs. 4%). CONCLUSIONS We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • Effect of Fluticasone Propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p

Gary T Ferguson - One of the best experts on this subject based on the ideXlab platform.

  • effect of Fluticasone Propionate salmeterol 250 50 μg or salmeterol 50 μg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    Summary Objectives COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50μg twice daily on moderate to severe exacerbations. Methods Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. Results In 782 patients with COPD (mean FEV 1 =0.94±0.36L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p p =0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% ( p Conclusions We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • effect of Fluticasone Propionate salmeterol 250 50 microg or salmeterol 50 microg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). Clinical improvements observed during run-in treatment with Fluticasone Propionate/salmeterol 250/50 were better maintained over 12 months with Fluticasone Propionate/salmeterol 250/50 than salmeterol. Adverse events were reported for a similar percentage of subjects across groups. A higher reporting of pneumonia was observed with Fluticasone Propionate/salmeterol 250/50 than salmeterol (7% vs. 4%). CONCLUSIONS We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • Effect of Fluticasone Propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p

Katharine Knobil - One of the best experts on this subject based on the ideXlab platform.

  • effect of Fluticasone Propionate salmeterol 250 50 μg or salmeterol 50 μg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    Summary Objectives COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50μg twice daily on moderate to severe exacerbations. Methods Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. Results In 782 patients with COPD (mean FEV 1 =0.94±0.36L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p p =0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% ( p Conclusions We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • effect of Fluticasone Propionate salmeterol 250 50 microg or salmeterol 50 microg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). Clinical improvements observed during run-in treatment with Fluticasone Propionate/salmeterol 250/50 were better maintained over 12 months with Fluticasone Propionate/salmeterol 250/50 than salmeterol. Adverse events were reported for a similar percentage of subjects across groups. A higher reporting of pneumonia was observed with Fluticasone Propionate/salmeterol 250/50 than salmeterol (7% vs. 4%). CONCLUSIONS We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • Effect of Fluticasone Propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p

Antonio Anzueto - One of the best experts on this subject based on the ideXlab platform.

  • effect of Fluticasone Propionate salmeterol 250 50 μg or salmeterol 50 μg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    Summary Objectives COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50μg twice daily on moderate to severe exacerbations. Methods Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. Results In 782 patients with COPD (mean FEV 1 =0.94±0.36L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p p =0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% ( p Conclusions We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • effect of Fluticasone Propionate salmeterol 250 50 microg or salmeterol 50 microg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). Clinical improvements observed during run-in treatment with Fluticasone Propionate/salmeterol 250/50 were better maintained over 12 months with Fluticasone Propionate/salmeterol 250/50 than salmeterol. Adverse events were reported for a similar percentage of subjects across groups. A higher reporting of pneumonia was observed with Fluticasone Propionate/salmeterol 250/50 than salmeterol (7% vs. 4%). CONCLUSIONS We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • Effect of Fluticasone Propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p

Richard Fei - One of the best experts on this subject based on the ideXlab platform.

  • effect of Fluticasone Propionate salmeterol 250 50 μg or salmeterol 50 μg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    Summary Objectives COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50μg twice daily on moderate to severe exacerbations. Methods Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. Results In 782 patients with COPD (mean FEV 1 =0.94±0.36L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p p =0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% ( p Conclusions We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • effect of Fluticasone Propionate salmeterol 250 50 microg or salmeterol 50 microg on copd exacerbations
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). Clinical improvements observed during run-in treatment with Fluticasone Propionate/salmeterol 250/50 were better maintained over 12 months with Fluticasone Propionate/salmeterol 250/50 than salmeterol. Adverse events were reported for a similar percentage of subjects across groups. A higher reporting of pneumonia was observed with Fluticasone Propionate/salmeterol 250/50 than salmeterol (7% vs. 4%). CONCLUSIONS We conclude that Fluticasone Propionate/salmeterol 250/50 is more effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The benefits of this reduction relative to the risk of a higher incidence of reported pneumonia should be considered. This study supports the use of Fluticasone Propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD.

  • Effect of Fluticasone Propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Respiratory Medicine, 2008
    Co-Authors: Gary T Ferguson, Antonio Anzueto, Richard Fei, Amanda Emmett, Katharine Knobil, Christopher Kalberg
    Abstract:

    OBJECTIVES COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of Fluticasone Propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. METHODS Patients received standardized treatment with Fluticasone Propionate/salmeterol 250/50 during a 1-month run-in, followed by randomization to Fluticasone Propionate/salmeterol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or hospitalization. RESULTS In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with Fluticasone Propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p